HRP20120168T1 - Postupak i međuprodukti kod dobivanja derivata n-(1-benzhidrilazetidin-3-il)-n-fenilmetilsulfonamida - Google Patents

Postupak i međuprodukti kod dobivanja derivata n-(1-benzhidrilazetidin-3-il)-n-fenilmetilsulfonamida Download PDF

Info

Publication number
HRP20120168T1
HRP20120168T1 HR20120168T HRP20120168T HRP20120168T1 HR P20120168 T1 HRP20120168 T1 HR P20120168T1 HR 20120168 T HR20120168 T HR 20120168T HR P20120168 T HRP20120168 T HR P20120168T HR P20120168 T1 HRP20120168 T1 HR P20120168T1
Authority
HR
Croatia
Prior art keywords
unbranched
carbon atoms
branched alkyl
formula
product
Prior art date
Application number
HR20120168T
Other languages
English (en)
Croatian (hr)
Inventor
Boffelli Philippe
Delthil Michel
Grondard Luc
Lampilas Maxime
Malpart Joel
Mutti St�Phane
Nait Bouda Lahlou
Rieke-Zapp Joerg
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of HRP20120168T1 publication Critical patent/HRP20120168T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HR20120168T 2004-10-14 2005-10-10 Postupak i međuprodukti kod dobivanja derivata n-(1-benzhidrilazetidin-3-il)-n-fenilmetilsulfonamida HRP20120168T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0410845A FR2876689B1 (fr) 2004-10-14 2004-10-14 Nouveau procede et intermediaires de preparation de derives de n-(1-benzhydryl-azetidin-3-yl)-n-phenyl-methylsulfonamide
PCT/FR2005/002489 WO2006040464A1 (fr) 2004-10-14 2005-10-10 Procede et intermediaires de preparation de derives de n-(1-benzhydryl-azetidin-3-yl)-n-phenyl-methylsulfonamide

Publications (1)

Publication Number Publication Date
HRP20120168T1 true HRP20120168T1 (hr) 2012-03-31

Family

ID=34953744

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20120168T HRP20120168T1 (hr) 2004-10-14 2005-10-10 Postupak i međuprodukti kod dobivanja derivata n-(1-benzhidrilazetidin-3-il)-n-fenilmetilsulfonamida

Country Status (32)

Country Link
US (3) US7429668B2 (pl)
EP (1) EP1802571B1 (pl)
JP (1) JP4971986B2 (pl)
KR (1) KR20070063540A (pl)
CN (1) CN101039903A (pl)
AR (1) AR051389A1 (pl)
AT (1) ATE534624T1 (pl)
AU (1) AU2005293453A1 (pl)
BR (1) BRPI0516526A (pl)
CA (1) CA2581781A1 (pl)
CR (1) CR9008A (pl)
CY (1) CY1112390T1 (pl)
DK (1) DK1802571T3 (pl)
EA (2) EA012523B1 (pl)
ES (1) ES2378181T3 (pl)
FR (1) FR2876689B1 (pl)
HR (1) HRP20120168T1 (pl)
IL (1) IL182277A0 (pl)
MA (1) MA29005B1 (pl)
ME (1) ME01297B (pl)
MX (1) MX2007004483A (pl)
NO (1) NO20072431L (pl)
PL (1) PL1802571T3 (pl)
PT (1) PT1802571E (pl)
RS (1) RS52132B (pl)
SG (2) SG144921A1 (pl)
SI (1) SI1802571T1 (pl)
TN (1) TNSN07115A1 (pl)
TW (1) TW200626542A (pl)
UY (1) UY29165A1 (pl)
WO (1) WO2006040464A1 (pl)
ZA (1) ZA200703011B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2925050B1 (fr) * 2007-12-14 2010-01-08 Sanofi Aventis Nouveau procede de preparation de derives d'azetidine
EP2448909B1 (en) * 2009-06-29 2013-05-01 Merz Pharma GmbH & Co. KGaA Method of preparing 1-amino-1,3,3,5,5-pentamethylcyclohexane
ES2416462T3 (es) * 2009-06-29 2013-08-01 Merz Pharma Gmbh & Co. Kgaa Método de preparación de neramexane.
CN107089918B (zh) * 2017-04-08 2020-06-16 迪嘉药业集团有限公司 一种盐酸二苯甲胺的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9714129D0 (en) * 1997-07-04 1997-09-10 Pfizer Ltd Azetidines
FR2805817B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
US6566356B2 (en) * 2000-03-03 2003-05-20 Aventis Pharma S.A. Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
FR2814678B1 (fr) * 2000-10-04 2002-12-20 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite

Also Published As

Publication number Publication date
JP2008516931A (ja) 2008-05-22
CY1112390T1 (el) 2015-12-09
NO20072431L (no) 2007-07-04
ES2378181T3 (es) 2012-04-09
DK1802571T3 (da) 2012-03-12
PL1802571T3 (pl) 2012-04-30
WO2006040464A1 (fr) 2006-04-20
US7429668B2 (en) 2008-09-30
ZA200703011B (en) 2009-09-30
AR051389A1 (es) 2007-01-10
TNSN07115A1 (fr) 2008-06-02
EA200801990A1 (ru) 2009-06-30
PT1802571E (pt) 2012-03-05
BRPI0516526A (pt) 2008-09-09
ATE534624T1 (de) 2011-12-15
UY29165A1 (es) 2006-05-31
MX2007004483A (es) 2007-06-13
JP4971986B2 (ja) 2012-07-11
ME01297B (me) 2013-12-20
US20080312205A1 (en) 2008-12-18
CN101039903A (zh) 2007-09-19
US20070244084A1 (en) 2007-10-18
MA29005B1 (fr) 2007-11-01
FR2876689B1 (fr) 2008-02-22
SG144921A1 (en) 2008-08-28
TW200626542A (en) 2006-08-01
EA200700842A1 (ru) 2007-08-31
FR2876689A1 (fr) 2006-04-21
SG144920A1 (en) 2008-08-28
CA2581781A1 (fr) 2006-04-20
EP1802571B1 (fr) 2011-11-23
US7652154B2 (en) 2010-01-26
AU2005293453A1 (en) 2006-04-20
KR20070063540A (ko) 2007-06-19
EA012523B1 (ru) 2009-10-30
US8071788B2 (en) 2011-12-06
IL182277A0 (en) 2007-07-24
CR9008A (es) 2007-10-01
SI1802571T1 (sl) 2012-03-30
EP1802571A1 (fr) 2007-07-04
RS52132B (sr) 2012-08-31
US20100087414A1 (en) 2010-04-08

Similar Documents

Publication Publication Date Title
AU2014373961B2 (en) 5-fluoro-4-imino-3-(alkyl/substituted alkyl)-1-(arylsulfonyl)-3,4-dihydropyrimidin-2(1H)-one and processes for their preparation
Wang et al. Chloride ion-catalyzed generation of difluorocarbene for efficient preparation of gem-difluorinated cyclopropenes and cyclopropanes
JP2018522724A (ja) シュウ酸アミド系配位子および銅触媒によるハロゲン化アリールのカップリング反応におけるその使用
JP6050358B2 (ja) ベンゾオキサジノンをアミンと反応させることによるテトラゾール置換アントラニル酸ジアミド誘導体の製造方法
RU2014128826A (ru) Дисоли малоновой кислоты и способ получения малонилдигалогенидов
JP6954456B2 (ja) スルファミン酸リチウムの製造方法及び新規スルファミン酸リチウム
Jiang et al. Selective monofluorination of active methylene compounds: the important role of ZnCl2 in inhibiting overfluorination
EP3812369B1 (en) A bromination method for m-diamide compounds
BR102013032003A2 (pt) Processo para a preparação de 4-amino-5-fluoro-3-cloro-6-(substituído)picolinato
JP6400869B1 (ja) ４，５−ジシアノ−２−（フルオロアルキル）イミダゾールの製造方法
IL185884A (en) A method for making converted pyrimidines
JP6407645B2 (ja) 芳香族化合物のパーフルオロアルキル化反応
US7569703B2 (en) Fluorinating agent and method for producing fluorine-containing compound using the same
US20190276429A1 (en) 4-(6-(2-(2,4-difluorophenyl)-1.1-difluoro-2-hydroxy-3-(5-mercapto-1h-1,2,4-triazol-1-yl)propyl)pyridin-3-yl)oxy)benzonitrile and processes of preparation
IL186564A (en) Method for producing nicotinic acid derivative or salt thereof
RS52132B (sr) Postupak intermedijeri u dobijanju derivata n-(1-benzhidril-azetidin-3-il)-n-fenil-metilsulfonamida
CN115724768B (zh) 一种双酰胺类化合物及其制备方法和应用
JP6994498B2 (ja) ３－アミノ－１－（２，６－二置換フェニル）ピラゾール類を調製する方法
JP6183053B2 (ja) テトラヒドロピラニルピリミジン化合物の製造方法
JP4738763B2 (ja) ３，７（９）−ジヒドロ−１ｈ−プリン−２，６−ジチオン化合物の製造方法
CN119409593A (zh) 对苯二腈作为氰化试剂的钴催化合成芳基腈的方法
JP2006124367A5 (pl)
TH2401005301A (th) กระบวนการสำหรับการเตรียม N-(1-เมทิลไซโคลโพรพิล)-2-(3-ไพริดินิล)-2h-อินดาโซล-4-คาร์บอกซาไมด์และอินเตอร์มีเดียตของสิ่งดังกล่าว